Developments in Laboratory Genetics
|
|
- Henry Wheeler
- 5 years ago
- Views:
Transcription
1 Developments in Laboratory Genetics Rachel Butler The Impact of Genomics on Public Health
2 Where are we now? Single gene disorders Core disorders Newborn screening (CF, MCAD) UKGTN for rare(r) disorders 695 gene / disease combinations (+67)
3 Where are we now? Single gene disorders Antenatal screening by QF-PCR D21S alleles D21S11 D13S628 D13S634 D18S535 D18S391 D13S742 D18S386 D21S1413 D21S1411
4 Where are we now? Single gene disorders Antenatal screening by QF-PCR Arrays for LD
5 Where are we going? Free-fetal DNA Next generation sequencing Personalised medicine
6 Free fetal DNA (ffdna) Applications Sexing Rhesus D Single gene disorders Aneuploidy analysis (RAPID)
7
8 Extraction of cell free fetal nucleic acids from maternal plasma Cell free maternal DNA (96.6%) Cell free fetal DNA (3.4%) Plasma Amount of cell free fetal DNA extracted is equivalent to 25 cells / ml plasma Cell free maternal RNA Cell free fetal RNA Maternal blood cells
9 Detecting ffdna in maternal blood.
10 Taken from Cell free fetal nucleic acids for non-invasive prenatal diagnosis; PHGF, 2009
11 Fetal sexing Taken from CMGS Audit
12 Single gene disorders DF508 / N G551D / N N / N N / Exp ffdna PND DF508 / N N / N G551D / N G551D / DF508 Cystic fibrosis PND N / N N / Exp Huntingtons
13 Single gene disorders Services now available for achondroplasia and thanatophoric dysplasia Others being piloted through RAPID for: Aicardi Goutiere, Alagille, Barth, Cockayne, Craniosynostoses, Dominant Ataxias, Ectodermal dysplasia, Ellis van Creveld, Fragile X, Friedrich s ataxia, Gylcogen storage diseases, Huntington s, Holt Oram, Inborn errors of metabolism, IPEX, Lissencephaly, Meckel gruber, Myotonic dystrophy, Neonatal diabetes/familial hyperinsulinaemias, Neurofibromatosis ½, Okihiro, Ornthine transcarbamylase deficiency, Osteogenesis imperfecta, Polycystic kidney disease, Rett syndrome, Retinoblastoma, Skeletal dysplasias, Smith Lemli Opitz, Spinal muscular atrophy, Spondylocostal dysostosis, TAR, Treacher Collins, Tuberous sclerosis 1/2, UPD 14, Wolcott-Rallison, X- linked Adrenoleukodystrophy and X-linked myotubular myopathy
14 Aneuploidy analysis: Various methods being developed and validated Quantitative analysis of SNPs in fetal specific mrna Extract RNA
15 Quantitative analysis of SNPs in fetal specific mrna PLAC 4 A / G A A G A Chr 21 Normal meiosis G A A A G A Non disjunction meiosis I (maternal) A G G A Normal A A A Trisomy 21
16 Quantitative analysis of SNPs in fetal specific mrna Analysis by MALDI-TOF (mass spectrometry) PLAC4 mrna ( ) is derived exclusively from fetal chromosome 21 PLAC4 mrna expressed in the placenta and is found in the plasma of pregnant women Normal fetus Normal fetus Trisomy 21 fetus Non informative 1 : 1 2 : 1 The Impact Lof et Genomics al., Nature on Public Med Health & PNAS, 25/04/
17 Results of shotgun sequencing of maternal plasma DNA Trisomy 13 n=1 Trisomy 18 n=2 Trisomy 21 n=9 Fan et al., PNAS Oct 2008
18 ffdna: Patient and healthcare benefits Non-invasive testing Reduced risk of miscarriage Earlier testing availability Significantly reduced cost of PND Reduction in invasive procedures
19 Next Generation Sequencing (NGS) Ability to sequence whole genome or selected regions of the genome On a scale massively larger than Sanger sequencing Applications Whole genome (100kg) Whole exome Targeted (panels)
20 Sanger sequencing NGS
21 And time
22 Application Example(s) Benefits over existing technology Screening multiple genes (in multiple patients) to determine treatment, surveillance Cardiac, cancer. Rare, specialist genetic conditions Turnaround, cost, high throughput analysis, sensitivity Provision of UK (and European) services. Whole genome sequencing Rare unknown syndromes Avoids unnecessary dx tests, answers & risk assessment for families Translational R&D Clinical trials, commercial services High throughput, cost, broad molecular characterisation Enhancement of existing services Invasive prenatal testing for Down s replaced by maternal blood test Cost, acceptability
23 e.g. Cardiac genetics Benefits of identifying at-risk family members: Appropriate surveillance and treatment Reduced morbidity for those not at risk Significant cost-savings Analysis of 13 genes Sanger sequencing NGS Cost TaT 24m 2m Acceptability No Yes
24 The problems of NGS Detection of unclassified variants Unexpected findings ELSI Data storage However, it is a fantastic development for diagnostic services!!!
25 NGS: Patient and healthcare benefits Increased sensitivity of genetic analysis for rare inherited disorders Opportunity for testing for really rare unknown genetic disorders Vastly reduced reporting times Reduced anxiety Reduction in tests ( ) before clinical diagnosis is made Potential to develop new diagnostic services
26 Personalised medicine Stratified medicine in cancer Pharmacogenetics Adverse affects Drug metabolism
27 The challenge: drugs don t work for most cancer patients Drug Response Rate, % Analgesics Cancer Source: Spears et al., Trends Mol Med, 2001; Lazarou et al., JAMA, 1998, 27
28 ...and we are struggling to produce new drugs The value of the largest 9 pharmaceutical companies fell by $0.6tn
29 But what s better for patients? benefits of personalised medicine
30 NSCLC Ref: T Mok IPASS trial. JCO (suppl):408s (abstract 8006) Progression-free survival in EGFR selected patients treated with Gefitinib
31 Exon 21 L858R mutation case study Iressa- 6 weeks & 4 months
32 Biomarkers that predict response in solid tumours Biomarker Tumour Drug / biomarker approved HER2 Breast / gastric Yes EGFR NSCLC Yes KRAS mcrc Yes (liver mets) c-kit / PDGFRA GIST Yes 1p36 / 19q13, MGMT, IDH1/2 Multiforme glioblastoma In common use BRAF (c-kit, NRAS) BRAF Metastatic melanoma (mcrc) Yes ALK-EML4 NSCLC 2013 MSI mcrc BRCA1/2 Breast? PTEN Prostate? PI3KCA mcrc?
33 Validated biomarkers predicting treatment or prognosis Solid tumours where either no or significant proportion of patients have no predictive or prognostic biomarker Tumour Germline
34 Pharmacogenetics Drug efficacy Adverse affects Pharmacodynamics the biochemical and physiological effects of drugs and the mechanisms of their actions Pharmacokinetics Pharmacokinetics, the movement and change of drugs in the body over a period of time
35 Warfarin Pharmacodynamics Pharmacokinetics
36 Warfarin dosing depends upon genotype at both VKORC1 and CYP2C9 loci
37 Well known pharmacogenetic associations Taken from
38 Personalised Medicine: Benefits for patients and Healthcare Treatment is tailored to the individual Should therefore work No / reduced side-effects (For cancer therapies) Oral drugs can be taken at home Considerably improved survival Significant cost-saving on drugs and readmissions
39 This is a snap-shot.. Many more service developments across UK Regional Genetic centres We re good at sharing!
Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation
Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation Dr Jenni Fairley Deputy Scheme Director (Molecular Pathology), GenQA, Edinburgh, UK From 1 st
More informationBig data vs. the individual liver from a regulatory perspective
Big data vs. the individual liver from a regulatory perspective Robert Schuck, Pharm.D., Ph.D. Genomics and Targeted Therapy Office of Clinical Pharmacology Center for Drug Evaluation and Research Food
More informationCMS will not implement the new tier codes for Medicare/Medicaid claims for calendar year 2012.
January 1, 2012 Re: 2012 AMA CPT Code Changes Dear Valued Client: The American Medical Association (AMA) has made Current Procedural Terminology (CPT) code changes to the 2012 edition of the CPT coding
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationGeneral Approach to Genetic Testing
Protocol General Approach to Genetic Testing (20491) (Formerly Genetic Testing for Inherited Disorders) Medical Benefit Effective Date: 01/01/14 Next Review Date: 09/14 Preauthorization Yes Review Dates:
More informationCURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi
2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationFONS Nové sekvenační technologie vklinickédiagnostice?
FONS 2010 Nové sekvenační technologie vklinickédiagnostice? Sekvenování amplikonů Sequence capture Celogenomové sekvenování FONS 2010 Sekvenování amplikonů Amplicon sequencing - amplicon sequencing enables
More informationImplementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges
Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges Frédérique Nowak - 21 october 2015 "Putting Science into Standards event:
More informationAccel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
More informationGenetics/Genomics: role of genes in diagnosis and/risk and in personalised medicine
Genetics/Genomics: role of genes in diagnosis and/risk and in personalised medicine Lynn Greenhalgh, Macmillan Cancer and General Clinical Geneticist Cancer Genetics Service Cancer is common 1 in
More informationGet a more complete picture into your patient's pregnancy with PreSeek
PRENATAL Expecting a baby is an exciting and mysterious time. And it s natural for your patient to wonder if they have a healthy pregnancy. Introducing PreSeek, the most comprehensive, single gene, cell-free
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationPersonalized Healthcare Update
Dr. Kai - Oliver Wesche Market Development Manager, Personalized Healthcare QIAGEN Personalized Healthcare Update Pioneering Personalized Medicine through Partnering TOMTOVOK BKM120 Zelboraf QIAGEN partners:
More informationEnabling Personalized
Molecular Enabling Personalized Diagnostics Medicine- Targeted Sequencing: NGS-based solutions Silvia Dorn Roel Reinders- Andreas Diplas Friday, 19.06.2015 Company Overview Founded in April 2011 Development
More informationpatients in the era of
Communicating with cancer patients in the era of personalized medicine September 9 th, 2017 Gerald Prager, M.D. Comprehensive Cancer Center Vienna Medical University of Vienna, Austria Gerald Prager, M.D.
More informationECMC cfdna consensus meeting
ECMC cfdna consensus meeting State of the art for cfdna technologies 24 th November 2014 Applications of ctdna analysis for drug development Potential of ctdna analysis to: Identify the right patients
More informationWhat is New in Genetic Testing. Steven D. Shapiro MS, DMD, MD
What is New in Genetic Testing Steven D. Shapiro MS, DMD, MD 18th Annual Primary Care Symposium Financial and Commercial Disclosure I have a no financial or commercial interest in my presentation. 2 Genetic
More informationNew Drug development and Personalized Therapy in The Era of Molecular Medicine
New Drug development and Personalized Therapy in The Era of Molecular Medicine Ramesh K. Ramanathan MD Virginia G. Piper Cancer Center Translational Genomics Research Institute Scottsdale, AZ Clinical
More informationNon-Mendelian inheritance
Non-Mendelian inheritance Focus on Human Disorders Peter K. Rogan, Ph.D. Laboratory of Human Molecular Genetics Children s Mercy Hospital Schools of Medicine & Computer Science and Engineering University
More informationQIAGEN Complete Solutions for Liquid Biopsy Molecular Testing
QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing Christopher Swagell, PhD Market Development Manager, Advanced Molecular Pathology QIAGEN 1 Agenda QIAGEN Solid Tumor Testing and Liquid Biopsy
More informationDr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory
Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory Personalised Therapy/Precision Medicine Selection of a therapeutic drug based on the presence or absence of a specific
More informationMEDICAL POLICY. SUBJECT: MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES (Excluding NSCLC and CRC) EFFECTIVE DATE: 12/21/17
MEDICAL POLICY SUBJECT: MOLECULAR PANEL TESTING OF PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationGenetics update and implications for (General) Practice
Genetics update and implications for (General) Practice May 12 th 2018 Women s Health Symposium Clearwater Estate Dr Kate Gibson MB BCh, MRCP, FRACP Topics NZ Clinical Genetics delivery New Technologies
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationBenefits and pitfalls of new genetic tests
Benefits and pitfalls of new genetic tests Amanda Krause Division of Human Genetics, NHLS and University of the Witwatersrand Definition of Genetic Testing the analysis of human DNA, RNA, chromosomes,
More informationRobert Beer
Robert Beer Robert.beer@wales.nhs.uk All Wales Medical Genetics Service Genetic Technologist Training Day 22 nd November 2017 Contents Stratified Medicine NHS EGFR Diagnostic Testing Services Cell free
More informationPrecision Medicine and Genetic Counseling : Is Yes always the correct answer?
Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Beverly M. Yashar, MS, PhD, CGC Director, Graduate Program in Genetic Counseling Professor, Department of Human Genetics. (yashar@umich.edu)
More informationDr C K Kwan. Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK
HA Convention 2013 Dr C K Kwan MBChB, FRCR, FHKCR, FHKAM, MPM, CPI, MAppMgt(Hlth) Associate Consultant, Queen Elizabeth Hospital, HKSAR Honorary member, Targeted Therapy Team, ICR, UK To personalize cancer
More informationWhole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute
Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes
More informationFitting the Treatment to the Patient Roche Personalized Healthcare. February 24, 2012
Fitting the Treatment to the Patient Roche Personalized Healthcare February 24, 2012 Roche Group Pharmaceuticals Roche Pharma Genentech Chugai Applied Science Molecular Professional Tissue Diabetes Care
More informationSingle Gene (Monogenic) Disorders. Mendelian Inheritance: Definitions. Mendelian Inheritance: Definitions
Single Gene (Monogenic) Disorders Mendelian Inheritance: Definitions A genetic locus is a specific position or location on a chromosome. Frequently, locus is used to refer to a specific gene. Alleles are
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK University Hospitals NHS Foundation Trust, Level 1, The Women s Centre John Radcliffe Hospital University Hospitals NHS Foundation Trust OX3
More informationPatient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017
Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of
More informationPrecision Medicine. Wendy Chung, MD PhD Director of Clinical Genetics Columbia University
Precision Medicine Wendy Chung, MD PhD Director of Clinical Genetics Columbia University What is precision medicine? Providing the right treatment for the right patient at the right time and engaging the
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationAMERICAN BOARD OF MEDICAL GENETICS AND GENOMICS
AMERICAN BOARD OF MEDICAL GENETICS AND GENOMICS Logbook Guidelines for Certification in Clinical Genetics and Genomics for the 2017 Examination as of 10/5/2015 Purpose: The purpose of the logbook is to
More informationGeneral Approach to Genetic Testing
Protocol General Approach to Genetic Testing (20491) Medical Benefit Effective Date: 01/01/17 Next Review Date: 11/18 Preauthorization Yes Review Dates: 01/11, 01/12, 09/12, 05/13, 09/13, 09/14, 09/15,
More informationGenetic Diseases. SCPA202: Basic Pathology
Genetic Diseases SCPA202: Basic Pathology Amornrat N. Jensen, Ph.D. Department of Pathobiology School of Science, Mahidol University amornrat.nar@mahidol.ac.th Genetic disease An illness caused by abnormalities
More informationAugust 17, Dear Valued Client:
August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationThe first non-invasive prenatal test that screens for single-gene disorders
The first non-invasive prenatal test that screens for single-gene disorders the evolution of NIPT A non-invasive prenatal test that screens multiple genes for mutations causing severe genetic disorders
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Building 9 Contact: Dr Catherine Sturgeon BioQuarter Tel: +44 (0)131-2426885 Little France Road Fax: +44 (0)131-242-6882 E-Mail: c.sturgeon@ed.ac.uk Websites: http://edqas.org EH16 4UX Proficiency Testing
More informationMedical Policy Update
Medical Policy Update Summer 2017 Highlights of recent medical policy revisions as well as any new medical policies approved by Prevea360 Health Plan s Medical Policy Committee are shown below. The Medical
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
SW Thames Regional Genetics Laboratory, Jenner Wing, SGUL Cranmer Terrace London SW17 0RE Contact: Mr John Short Tel: +44 (0) 208 725 5332 Fax: +44 (0) 208 725 3440 E-Mail: swtrgl@stgeorges.nhs.uk Website:
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationGENETIC TESTING AND COUNSELING FOR HERITABLE DISORDERS
Status Active Medical and Behavioral Health Policy Section: Laboratory Policy Number: VI-09 Effective Date: 03/17/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More information9/23/2014. Wisconsin Association of Physician Assistants October 10, 2014
Personalized (Precision) Medicine Wisconsin Association of Physician Assistants October 10, 2014 Disclosures I am an employed by Promega Corporation, a Madison based international biotechnology company
More informationMolecular biology of colorectal cancer
Molecular biology of colorectal cancer Phil Quirke Yorkshire Cancer Research Centenary Professor of Pathology University of Leeds, UK Rapid pace of molecular change Sequencing changes 2012 1,000 genomes
More informationFluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS
APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor
More informationGenetic Testing for Inherited Conditions
Genetic Testing for Inherited Conditions Policy Number: 2018-101 Effective Date: January 26, 2018 Review Date: January 26, 2018 Next Review Date: January 26, 2019 Important Information - Please Read Before
More informationCurrent and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian
Current and future applications of Molecular Pathology Kathy Walsh Clinical Scientist NHS Lothian Molecular Pathology in Solid tumours Cancer type Genes tested Purpose Associated treatments Non small cell
More informationLIST OF INVESTIGATIONS
Karyotyping: K001 K002 LIST OF INVESTIGATIONS SAMPLE CONTAINER TYPE cells For Karyotyping [Single] cells For Karyotyping [Couple] Vacutainer Vacutainer 7-8 7-8 K003 Fetal Blood Sample For Karyotyping Vacutainer
More informationMEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers
POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,
More informationExternal Quality Assurance in Genetics Laboratories
Genetics Quality and Accreditation workshop External Quality Assurance in Genetics Laboratories Farrah Khawaja Deputy Scheme Director UK NEQAS for Molecular Genetics The Royal Infirmary of Edinburgh Molecular
More informationReproducibility with zebrafish models of human health and disease
Reproducibility with zebrafish models of human health and disease Monte Westerfield, University of Oregon, Eugene, USA Sponsored by the Office of the Director National Institutes of Health, the National
More informationLiquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationOriginal Policy Date
MP 2.04.76 Genetic Counseling Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created Local Policy/ 12:2013 Return to Medical Policy Index Disclaimer
More information24-Feb-15. Learning objectives. Family genetics: The future??? The traditional genetics. Genetics and reproduction in early 2015.
Learning objectives Family genetics: The future??? Peter Illingworth Medical Director IVFAustralia Understand how genetic problems may affect successful conception Consider the possible conditions and
More informationMOC MGP General Molecular Genetics I (Mandatory 75-Question Module) assay validation; sensitivity; oligodendroglioma, FISH CAP lab accreditation;
MOC MGP General Molecular Genetics I (Mandatory 75-Question Module) assay validation; sensitivity; oligodendroglioma, FISH CAP lab accreditation; phase II deficiency oligodendroglioma; chemotherapy response
More informationCDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
More informationSomatic cancer applications of NGS in in vitro Diagnostics.
Somatic cancer applications of NGS in in vitro Diagnostics. Nitin Udar PhD In Vitro Diagnsotics Division Illumina, Inc. 2013 Illumina, Inc. All rights reserved. Illumina, IlluminaDx, BaseSpace, BeadArray,
More informationIntegrating Genetics Technology into a Health Care System
Integrating Genetics Technology into a Health Care System Wylie Burke MD PhD Department of Medical History and Ethics University of Washington, Seattle WA Trends Medical genetics/ specialty primary care
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationApproach to the Genetic Diagnosis of Neurological Disorders
Approach to the Genetic Diagnosis of Neurological Disorders Dr Wendy Jones MBBS MRCP Great Ormond Street Hospital for Children National Hospital for Neurology and Neurosurgery What is a genetic diagnosis?
More informationPersonalised medicine: Past, present and future
Kathmandu, Bir Hospital visit, August 2018 Personalised medicine: Past, present and future Rodney J. Scott University of Newcastle, NSW, Australia & Hunter Area Pathology Service Current Medical Care Started
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationMolecular Diagnostics Overview JAN A. NOWAK, PHD, MD PATHOLOGY AND LABORATORY MEDICINE MOLECULAR DIAGNOSTICS LABORATORY FEBRUARY 15, 2018
Molecular Diagnostics Overview JAN A. NOWAK, PHD, MD PATHOLOGY AND LABORATORY MEDICINE MOLECULAR DIAGNOSTICS LABORATORY FEBRUARY 15, 2018 Some Key Points Molecular Testing has applications in every section
More informationNGS IN ONCOLOGY: FDA S PERSPECTIVE
NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for
More informationGenetics Mutations 2 Teacher s Guide
Genetics Mutations 2 Teacher s Guide 1.0 Summary Mutations II is an extension activity, which reviews and enhances the previous Core activities. We recommend that it follow Mutations and X-Linkage. This
More informationSingle-Gene. NGS Sequencing Throughput 1 sample 48 Samples
For immediate release Hong Kong Sanatorium & Hospital State-of-the-Art Molecular Pathology Laboratory Introduces First-in-Hong Kong Next Generation Sequencing for Clinical Diagnostic Service (8 November
More informationPRECISION INSIGHTS. Liquid GPS. Blood-based tumor profiling and quantitative monitoring. Reveal more with cfdna + cfrna.
PRECISION INSIGHTS Liquid GPS Blood-based tumor profiling and quantitative monitoring Reveal more with cfdna + cfrna www.nanthealth.com Why Blood-Based Tumor Profiling? Although tissue-based molecular
More informationQIAGEN. Sample & Assay Technologies. New Approaches in Biomarker Detection. SEAP/SEC/SEPAF Zaragoza May 2011
QIAGEN New Approaches in Biomarker Detection SEAP/SEC/SEPAF Zaragoza May 2011 Dr. Stephen Little Vice President Personalized Healthcare - 1 - DxS is a Personalised Medicine Company that meets the needs
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationMEDICAL GENETICS CLINICAL CARE ROTATION
Medical Genetics Clinical Care Rotation 1 MEDICAL GENETICS CLINICAL CARE ROTATION Overview: The Medical Genetics Clinical Care Rotation (MGC) is the backbone of the clinical genetics experience for the
More informationGenetic Testing: who, what, why?
Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk
More informationDevelopment of Circulating Tumor DNA
Development of Circulating Tumor DNA Title of presentation Arial Bold 30pt in White Biomarkers Secondary title 22pt using Arial Next in White Generation Sequencing Brian Dougherty PhD, MBA Translational
More informationCorporate Medical Policy
Corporate Medical Policy Carrier Screening for Genetic Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: carrier_screening_for_genetic_disease 12/2013 7/2017 7/2018 7/2017
More informationNGS ONCOPANELS: FDA S PERSPECTIVE
NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration
More informationACMG/CAP Cytogenetics CY
www.cap.org Cytogenetics Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services ACMG/CAP Cytogenetics CY Analyte CY Challenges per Shipment
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISORDER/CONDITION POPULATION TRIAD Submitting laboratory: Exeter RGC Approved: Sept 2013 1. Disorder/condition
More informationWhat s in your genes? Whole genome sequencing and its impact on personalized medicine
What s in your genes? Whole genome sequencing and its impact on personalized medicine Adrianna San Roman Clare Malone Leah Liu Photo by Micah Baldwin Personalized Medicine Tailoring of medical care based
More informationLiquid biopsy in lung cancer: The EGFR paradigm
Liquid biopsy in lung cancer: The EGFR paradigm Lynette M. Sholl, M.D. Brigham and Women s Hospital Dana Farber Cancer Institute Department of Pathology Boston, MA Disclosure of Relevant Financial Relationships
More informationGenetic screening. Martin Delatycki
7 Genetic screening Martin Delatycki Case study 1 Vanessa and John are planning a family. They see their general practitioner and ask whether they should have any tests prior to falling pregnant to maximise
More informationTHE CHROMOSOMAL BASIS OF INHERITANCE CHAPTER 15
THE CHROMOSOMAL BASIS OF INHERITANCE CHAPTER 15 What you must know: Inheritance in sex-linked genes. Inheritance of linked genes and chromosomal mapping. How alteration of chromosome number or structurally
More informationFormal Genetics of Humans: Modes of Inheritance. Dr. S Hosseini-Asl
Formal Genetics of Humans: Modes of Inheritance Dr. S Hosseini-Asl 1 Autosomal dominant (AD) a: Wild type (Wt) allele A: Mutant allele aa: Normal phenotype Aa: Affected (heterozygous) AA: Affected (homozygous)
More informationDate of Birth Gender Ethnicity/Family History Male Female Unknown. (Institutional Billing only. We DO NOT bill patients directly.)
PATIENT INFORMATION Last Name First M.I. CLINICAL LABORATORY Date of Birth Gender Ethnicity/Family History Male Female Unknown Molecular Diagnotics Patient or Sample ID# Institutional Account # (415) 514-8488
More informationPREVENTION OF HAEMOGLOBINOPATHIES: New methodologies and procedures Non-invasive Prenatal Diagnosis
PREVENTION OF HAEMOGLOBINOPATHIES: New methodologies and procedures Non-invasive Prenatal Diagnosis Marina Kleanthous Cyprus School of Molecular Medicine The Cyprus Institute of Neurology and Genetics
More informationWhy did this happen? Genetic and teratologic considerations in CHD Jennifer Kussmann, MS,CGC. The Children's Mercy Hospital, 2014.
Why did this happen? Genetic and teratologic considerations in CHD Jennifer Kussmann, MS,CGC The Children's Mercy Hospital, 2014. 03/14 Risk factors Family history Maternal medical condition/ illness Monochorionic
More informationMolecular Genetic Pathology CC Exam Module Study Guide
Registrants for the MGP only or combined Primary/MGP CC exam must take the mandatory general MGP module plus any elective HEM modules selected during registration. CC MGP General Molecular Genetics I (Mandatory
More informationGenetics in Primary Care Curriculum Statement 6. Dr Dave Harniess PCME Stockport
Genetics in Primary Care Curriculum Statement 6 Dr Dave Harniess PCME Stockport Learning Objectives Understanding of genetic component of disease Screening for genetic conditions and risk assessment in
More informationLa biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro
La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Panel Testing of Cancers to Identify Targeted Therapies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_panel_testing_of_cancers_to_identify_targeted_therapies
More informationGENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)
CANCER (NSCLC) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
More informationThe Center for PERSONALIZED DIAGNOSTICS
The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)
More information